Medical and economical impact of bone metastases in lung cancer patients: a prospective French national, multicentric study (GFPC 06-01 study): PD6-3-3

Bone metastases are an important emerging problem in patients with lung cancer and are leading to increasing consumption of health care resources. To assess the epidemiology, the management strategies and the costs of bone metastases in lung cancer; to model the management of these patients by a Markov model in order to evaluate the effectiveness of different therapeutic strategies. prospective, national, multicentric, observational, epidemiological study planned to include 500 patients between may 2006 and may 2007, with a one year follow up, a monthly report of skeletal-related events and resources consumptions. The economic analysis is limited to the direct costs with the health care payer’s perspective. At this time, 404 patients are included by 36 centres: men: 77,2%, median age: 61 (39-84) years, non small cell lung cancer: 90%. Bone diagnosis metastases is made by scintigraphy (59.7%), standard radiology or RMI (3.4%), and bone-scan (36.9%). At inclusion the median number of lesions was 4; 74.4% of patients receive an analgesic treatment, 41.5% a biphosphonates therapy (zoledronate in 83% of cases), 20.5% a radiotherapy and 5%.had a bone-surgery. complete demographic, clinical and economical datas will be presented at the IASCL meeting.